Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.

Br J Cancer · 2016 · PMC4984795 · PMID 27031850

Europe PMC DOI

hedged sentence

0.1002

closest p · 2.0× alpha

0.1002

boldest claim

The sentences

did not reach statistical significanceP =0.1002not close (p > 0.1)

However, the difference in overall survival (OS) – the primary study end point – did not reach statistical significance (12.1 vs 10.1 months; HR, 0.87; P =0.1002; Ohtsu et al , 2011 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.